Results 71 to 80 of about 35,727 (251)
Zebrafish and CRISPR—A synergistic approach to decipher and cure human diseases
Animal Models and Experimental Medicine, EarlyView.Zebrafish, with high genetic homology to humans, serves as a powerful vertebrate model for disease modeling and drug discovery. Integration of CRISPR/Cas9 technology enables precise genome editing, facilitating the development of translational models for human diseases.
Manikandan Sivaprakasam +4 more
wiley +1 more source
Bone mineral disorder in chronic kidney disease: Klotho and FGF23; cardiovascular implications
Nefrología (English Edition), 2016 Cardiovascular factors are one of the main causes of morbidity and mortality in patients with chronic kidney disease. Bone mineral metabolism disorders and inflammation are pathological conditions that involve increased cardiovascular risk in chronic ...
Laura Salanova Villanueva +4 more
doaj +1 more source
Animal Research and One Health, EarlyView.Our paper systematically reviews the intestinal structure, function, and microbiota of ostriches, along with strategies for improving their gut health. We analyze how these factors collectively influence intestinal homeostasis and ostrich welfare, emphasizing probiotics as a promising intervention to enhance gut health, boost population well‐being, and
Zi‐Qun Zhang +6 more
wiley +1 more source
Fibroblast growth factor 23 and cardiovascular disease in patients with chronic kidney disease [PDF]
, 2018 Chronic kidney disease (CKD) has been known to be associated with an increased risk of cardiovascular (CV) mortality and morbidity in Japan. Although traditional risk factors contribute to the development of CV disease in CKD patients, they cannot fully ...
NITTA Kosaku
core +2 more sources
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Arthritis &Rheumatology, EarlyView.Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami +10 more
wiley +1 more source
Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics
British Journal of Clinical Pharmacology, EarlyView.Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay +5 more
wiley +1 more source
Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
Toxins, 2020 Cardiovascular (CV) disease is highly prevalent in the population with chronic kidney disease (CKD), where the risk of CV death in early stages far exceeds the risk of progression to dialysis.
Merita Rroji +2 more
doaj +1 more source
The role of FGF23/Klotho in mineral metabolism and chronic kidney disease [PDF]
, 2013 Chronic kidney disease (CKD) is a global health burden of growing incidence and prevalence. As renal function declines disturbances in mineral metabolism, such as hyperphosphatemia and secondary hyperparathyroidism, inevitably develop. These metabolic
Olauson, Hannes
core +1 more source
BMEMat, EarlyView.This study develops a nano‐enzyme patch (ezPatch) targeting bone interfaces. Utilizing ligand‐to‐metal charge transfer (LMCT) catalysis and bone‐targeting ligands on copper nanosheets, ezPatch simultaneously scavenges reactive oxygen species (ROS) and generates oxygen in situ at bone‐losing sites.
Yi Chen +12 more
wiley +1 more source
Management of chronic kidney disease–mineral and bone disorder: Korean working group recommendations
Kidney Research and Clinical Practice, 2015 For Korean dialysis patients, chronic kidney disease–mineral bone disorder is a serious burden because of cardiovascular calcification and mortality.
Eunah Hwang +4 more
doaj +1 more source